How does it work?

TrueSight sits inside the Lifestyle Rx platform and draws on every piece of data a patient’s care has generated. That includes intake forms, consult notes, prescriptions and dose changes, confirmed medication intake, weight, steps, activity data, and anything the patient has written in their own words, in Arabic or English. It also tracks order and delivery history, and how the patient actually uses the app, including what they ignore.

From that combined picture, the system maintains a running account of each patient. It tracks stable facts and routines, records what the patient has already told the care team, and notes what they have already declined. Rather than locking onto a single explanation when something changes in the data, it holds several possibilities open at once, each tied to the evidence that supports it and the evidence that would rule it out. Then it surfaces one thing per day worth telling the patient, with a clear explanation of what that judgment is based on. If new information weakens an earlier reading, the system retracts it.

Before a consult, it hands the physician a structured summary of the preceding month. The appointment starts from context rather than a cold reconstruction. TrueSight does not diagnose, prescribe, or treat. Clinical decisions stay with licensed clinicians. The system organises and presents information the patient has already provided.

By design, it is quiet. It surfaces one small prompt at a time, usually resolved with a single tap, and says nothing on days when there is nothing worth saying. When a patient shares context, travel, hospitalisation, or fasting during Ramadan, it adjusts rather than flagging normal life as a missed target. In one beta example, a patient’s weight and meal patterns shifted over a week. Instead of logging it as non-adherence, the system asked directly whether anything had changed. The patient explained they were staying at a hospital with a family member. The doctor saw context, not a gap.

A second phase is planned shortly after the current beta. It will extend truesight into consultations as a real-time transcription scribe, capturing physician-patient conversations so nothing said in the room is lost. Patients consent during Lifestyle Rx onboarding, and all DarDoc physicians operate under a standing agreement to use the tool. Lab results will also feed into the system, connecting what is said in the room with a patient’s digitised biomarker history.

TrueSight is live now for Lifestyle Rx members, starting with iOS users. Android availability follows after the iOS release. Beta enrolment numbers have not been disclosed. The tool is not connected to DarDoc’s separate partnership with Novo Nordisk.

• Data sources: consult notes, prescriptions, confirmed medication intake, weight, steps, and activity
• Patient-written input accepted in Arabic and English
• Tracks app usage patterns, including ignored prompts
• Surfaces one insight per day, with visible reasoning
• Retracts earlier readings when new evidence contradicts them
• Phase two adds real-time consult transcription and lab data integration

Why does it matter?

The gap between appointments is where most chronic disease management either holds or falls apart. A patient on a GLP-1 programme, for example, might see their physician once a month. Everything that happens in the weeks between visits, the missed doses, the travel, the side effects quietly endured, rarely makes it into a clinical record in any structured way. TrueSight is built for exactly that space.

‘Healthcare has traditionally focused on the treatment itself, but outcomes are shaped by what happens between appointments,’ said Keswin Suresh, co-founder of DarDoc. ‘That’s where adherence and persistence matter most.’

And the ambition here goes beyond reminders. The system is designed to carry the thread of a patient relationship forward continuously, so that clinical conversations start from where the patient actually is. That is a meaningful shift from how most digital health tools currently work, where data is collected but rarely synthesised into something a clinician can act on immediately.

The context

DarDoc was founded in 2021 by Samer Masri and Keswin Suresh and holds DHA digital clinic, home healthcare, and pharmacy licences, alongside DOH accreditation in Abu Dhabi. Its Lifestyle Rx clinic covers weight loss, peptides, skin, and sexual health. The company also runs Pulse OS, a B2B platform supporting gyms, hotels, recovery centres, and corporate wellness partners across the UAE. DarDoc is an alumnus of the Mohammed Bin Rashid Innovation Fund Innovation Accelerator, an initiative of the UAE Ministry of Finance.

The launch sits squarely within a wider push across the UAE and GCC to make AI a functional part of clinical workflows rather than a background capability. The UAE’s National Strategy for Artificial Intelligence and the broader health ambitions embedded in Abu Dhabi’s and Dubai’s respective health authority roadmaps have created real appetite for tools that move beyond data collection toward clinical intelligence. DarDoc claims truesight is the first system of its kind in the UAE. So the real question, for the physicians and health system planners watching this beta, is whether the data it surfaces actually changes what happens in the room. That answer will come with time and scale. But the design logic is sound, and the problem it is solving is real.

The post DarDoc launches AI intelligence layer that reads a patient’s full history before the doctor walks in appeared first on DH Arab.

SEHA, a subsidiary of PureHealth, the Middle East’s largest healthcare group, officially launched the Adult Cardiac Surgery Programme and the Advanced Structural Heart Disease Interventional Cardiology Programme at the Al Ain facility. Both programmes became operational on 9 December 2025 and are already producing results at a pace that suggests significant local need had gone unmet.

How does it work?

The Adult Cardiac Surgery Programme covers a broad range of complex operations, including coronary artery bypass grafting, heart valve surgery, complex aortic procedures, and combined cardiac surgeries. Since December, the programme has completed 74 such procedures.

The Structural Heart Disease programme takes a different approach, focusing on catheter-based interventions rather than open surgery. It has completed 52 procedures since launch, with particular focus on elderly and high-risk patients who may not be suitable candidates for conventional surgery. The procedures offered include:

• Transcatheter aortic valve replacement (TAVR)
• Transcatheter mitral valve repair using MitraClip or Pascal devices
• Left atrial appendage closure
• Closure of complex cardiac defects

Both programmes operate through a shared multidisciplinary model, pulling together cardiologists, cardiac surgeons, anaesthetists, intensive care specialists, and cardiac rehabilitation teams. The goal is continuity, one clinical team supporting a patient from diagnosis through recovery and follow-up, rather than handing off between departments.

Why does it matter?

Geography shapes access to healthcare, and Al Ain’s position as a major city away from Abu Dhabi’s coastal health infrastructure has historically meant that residents with serious cardiac conditions faced longer journeys to reach specialist care. Bringing TAVR, bypass surgery, and structural heart interventions to Sheikh Tahnoon Medical City shortens that journey considerably.

But the programmes also carry a quality argument, not just an access one. Dr. Ali Rashed Al Shamsi, Consultant Cardiologist and Head of the Cardiology and Cardiac Surgery Department at the facility, said the launch supports “timely access, multidisciplinary decision-making, and more personalised care for complex heart conditions within the UAE.” The emphasis on decision-making is important. Structural heart conditions, particularly in older patients, often sit on the boundary between surgical and interventional options. Having both disciplines under one roof, with a shared team, improves the quality of those decisions.

The programmes are also linked to academic collaboration with international institutions, aimed at transferring specialist knowledge and building local clinical capability over time. Research and training outputs are part of the design, not an afterthought.

The context

Abu Dhabi has been deliberate about expanding specialist healthcare capacity within the emirate, a goal that sits comfortably alongside the UAE’s broader Vision 2030-aligned health strategies and the Department of Health Abu Dhabi’s ongoing push to reduce medical tourism outflows. When patients seek treatment abroad for conditions that could be managed locally, it represents both a financial drain and a signal of gaps in the domestic system.

PureHealth, which manages SEHA alongside a portfolio that includes Daman health insurance, Sheikh Shakhbout Medical City, and international assets such as Circle Health Group in the UK and Ardent Health Services in the US, has been expanding specialist capacity across its UAE network. Sheikh Tahnoon Medical City is positioned as one of the group’s centres of excellence for specialised and academic care, and these two cardiac programmes fit that positioning.

The GCC’s cardiovascular disease burden is well documented. Rates of diabetes, hypertension, and obesity across the region create a large and growing population at risk of heart disease. Building surgical and interventional capacity closer to where those patients live is a long-term infrastructure investment. Al Ain’s 120-plus procedures in under 90 days suggest the demand is real and immediate.

The post Abu Dhabi brings advanced heart surgery home with two new cardiac programmes at Al Ain medical city appeared first on DH Arab.

What’s the news?

KPMG selected SDM from a field of ten finalists at the Saudi edition of its annual competition, which was held for the sixth time this year. The judging panel assessed companies across several criteria:

• Strength and originality of the technology
• Market potential and customer traction
• Long-term growth potential
• Quality of the pitch

SDM develops AI-driven diagnostic tools, with a particular focus on retinal imaging technology designed to support early detection of chronic and systemic diseases. The other finalists included Authena, Carevision, Eyego, LinusBio, Nommas, Plantafarm, Terraxy, Think AI, and WhiteHelmet, spanning sectors from agriculture and food supply chains to construction and space technology.

Why does it matter?

SDM’s win is more than a competition result. It points to something broader happening in Saudi Arabia’s technology sector. Naif AlObaidallah, CEO of SDM, was direct about the significance: “What we have built was born in Saudi Arabia, developed by Saudi talent, and designed for the healthcare needs of our people.” That framing matters. Saudi Arabia has spent years positioning itself as a consumer and importer of global technology. The push now, embedded in Vision 2030, is to become a producer and exporter of it.

Samer Abdallah, Partner and Board Member at KPMG in the Middle East and chair of the judging panel, said SDM stood out for combining a credible technology proposition with clear real-world application and the ability to scale. In health-tech, that combination is harder to achieve than it sounds. Many AI diagnostic tools struggle to move from pilot to clinical adoption. SDM’s traction with customers was clearly part of what convinced the panel.

The context

The KPMG Global Tech Innovator competition runs across more than 20 countries, with national winners competing at a single global final. It gives early and growth-stage technology companies exposure to KPMG’s advisory networks, access to investors, and a platform that most startups would otherwise take years to reach.

For the Gulf health-tech sector, moments like this carry real weight. The UAE has its own aggressive digital health agenda, and Saudi Arabia’s Vision 2030 has made health system modernisation a stated national priority. AI-assisted diagnostics, particularly tools that can support detection of conditions like diabetes and cardiovascular disease, which carry a significant disease burden across the GCC, are exactly the kind of home-grown solutions policymakers have been calling for.

So when SDM takes the stage in Lisbon in November, it will carry more than a competition title. It will carry a case study in what Saudi deep tech can look like when the conditions are right.

The post Saudi health-tech firm SDM wins KPMG’s 2026 Global Tech Innovator competition appeared first on DH Arab.

How will it work?

The delegation met with leadership at several leading academic medical centers and research institutions, though specific names were not disclosed in early reports. The focus was on identifying areas of mutual interest that could translate into formal agreements, research exchanges, and capacity-building programs for UAE-based professionals.

Priority areas from the visit included:

• Genomic medicine and population-level genetic research
• Early disease detection technologies
• AI-assisted diagnostics and clinical decision support
• Academic partnerships for training and research development
• Innovation pipelines connecting US institutions with UAE healthcare systems

The structure of these engagements suggests the UAE is looking for more than licensing deals. The emphasis on research and academic collaboration points toward longer-term institution-building, the kind that produces local expertise rather than imported solutions.

Why does it matter?

For the UAE, this is about more than prestige visits. The country has made health sovereignty a strategic priority, and that requires homegrown research capacity, not just world-class hospitals. Genomics is a particular gap. Population-scale genetic data programs need years of investment before they generate clinically useful insights, so the urgency to start, and to start with credible partners, is real.

AI in diagnostics is the other pressure point. Gulf health systems are dealing with a familiar set of chronic disease burdens, diabetes, cardiovascular disease, obesity-related conditions, and AI tools trained on relevant population data could meaningfully improve early detection rates. But those tools need to be built with, or at least validated against, local data. That makes academic partnerships a precondition, not an optional extra.

The context

This visit sits within a broader pattern of UAE health diplomacy that has accelerated since the post-pandemic period. The country’s National Strategy for Advanced Technology and its commitments under various Vision-aligned frameworks have all pointed toward healthcare as a sector where the UAE wants to move from consumer to contributor. Hosting COP28 last year, with its significant health and climate agenda, also raised the profile of UAE health policy internationally.

Boston and New York are not random choices. Both cities concentrate an unusual density of academic medical institutions, biotech companies, and research hospitals. For a delegation focused on future medicine, these are the right rooms to be in. And if the partnerships announced in the coming months reflect the ambition of the conversations, the UAE’s research ecosystem could look meaningfully different by the end of the decade.

The post UAE health minister leads US institutional tour to build future medicine partnerships appeared first on DH Arab.

What’s the news?

Egyptian President Abdel Fattah Al-Sisi met with Orange Group CEO Christel Heydemann in late September, alongside Communications Minister Raafat Hendy and senior Orange executives for the Middle East, Africa, and Egypt. The meeting covered telecommunications cooperation, digital skills, and technology investment, but the sharpest ask from the Egyptian side was direct: join the second phase of the national digital health project.

Al-Sisi called on Orange to contribute to that second phase specifically in digital infrastructure, cloud computing, cybersecurity, and systems integration. He also urged the group to scale up training programmes that prepare young Egyptians for jobs in AI, data analytics, and cloud computing, including through internationally recognised professional certifications delivered via global technology partners.

Orange’s announced commitments include the 200,000-person training initiative, the €25 million startup fund targeting AI and advanced technologies, and laboratory installations at a number of Egyptian universities. Heydemann said Orange’s Egypt work could act as a reference model for other markets across the region, particularly in Africa.

Why does it matter?

Digital health is one of the most investment-heavy and strategically sensitive sectors in any national tech agenda. Egypt’s first phase of its national digital health project laid groundwork for electronic medical records, telehealth infrastructure, and health data systems. Bringing a major telecoms and technology group like Orange into the second phase would add serious cloud and connectivity muscle to that build-out.

The workforce angle is just as significant. Egypt has one of the largest youth populations in the Arab world, and the government has made digital skills central to its economic strategy. A commitment from Orange to deliver AI and cybersecurity training at scale, with recognised certifications attached, addresses a real gap. Skilled talent is consistently cited by regional tech investors as a constraint on growth.

Still, important details are missing. The presidency’s statement did not specify a timetable for implementation, how the €25 million startup fund will be distributed, or which universities will receive the new laboratories. Those gaps matter for anyone trying to assess what this partnership will actually deliver.

The context

Across the GCC and broader Arab world, governments are racing to build out digital health infrastructure as part of wider national transformation programmes. Saudi Vision 2030 and the UAE’s various health and AI strategies have pushed regional ambitions higher and raised expectations for what technology partnerships should look like. Egypt is working on a different budget and scale, but the direction is the same.

Orange has a long-standing presence in Egypt and the wider Middle East and Africa region. Its involvement in digital education and smart platforms gives it credibility beyond pure connectivity. But the move to position Egypt as a model for African markets is notable. It suggests Orange sees the country not just as a local market, but as a proof-of-concept for a broader regional and continental strategy.

For health technology companies, infrastructure providers, and investors tracking where the next wave of digital health contracts will land, Egypt’s second-phase ambitions are worth watching closely.

The post Egypt presses Orange Group to join digital health expansion as tech investment deepens appeared first on DH Arab.

What’s the news?

Hyperfine, the US-listed health technology company behind the Swoop portable brain MRI system, has named Kuwait-based Roots Pharmaceutical as its exclusive distributor for Kuwait and the UAE. The agreement covers market development, regulatory support, product education, and, once local clearances are secured, full commercial operations across both countries.

Why does it matter?

Stroke and neurodegenerative diseases are among the most time-sensitive conditions in medicine. Getting a brain scan quickly, and close to the patient, can change outcomes. The Swoop system is FDA-cleared, AI-powered, and portable enough to be used at the bedside, in emergency departments, or in facilities that could never house a conventional MRI unit. For the UAE and Kuwait, both of which are actively expanding their diagnostic infrastructure, that flexibility has real clinical value.

Roots Pharmaceutical brings established relationships across the GCC and a track record of launching specialist medical technologies in the region. So this is not a paper distribution deal. It is a commercial push backed by local knowledge.

The context

The UAE’s health sector is a central pillar of national development strategy. Investment in advanced diagnostics, AI-assisted care, and hospital infrastructure has accelerated sharply in recent years. Kuwait is on a similar path. Both markets are moving toward more patient-centric models of care, which means bringing diagnostics closer to where patients actually are, rather than moving patients to where machines happen to be.

Hyperfine has built its international strategy around exactly this idea. The Swoop system has already been deployed in:

• Intensive care units and emergency departments
• Stroke and neurology wards
• Remote and underserved facilities with limited infrastructure
• Research and academic medical centres

The GCC expansion adds two high-investment markets to that network. Pending local regulatory clearance, clinical adoption in Kuwait and the UAE could follow within the coming months.

The post Hyperfine brings portable brain MRI to Kuwait and the UAE through Roots Pharmaceutical deal appeared first on DH Arab.

The Abu Dhabi-based healthcare group has installed what it describes as the GCC’s first AI-powered catheterisation laboratories at Burjeel Hospital Abu Dhabi and Burjeel Specialty Hospital in Sharjah. The technology at the centre of both facilities is Siemens Healthineers’ ARTIS icono.vision platform, a system that combines high-definition imaging, real-time procedural guidance, advanced 3D visualisation, and automated workflows into a single operating environment.

At Burjeel Hospital Abu Dhabi, the installation has doubled the hospital’s cath lab capacity. That matters in a city where demand for specialised cardiovascular care is growing steadily and where the population skews toward risk factors, including diabetes and hypertension, that drive complex cardiac cases.

How does it work?

The core of the platform is a feature called OPTIQ AI. It builds on earlier imaging adjustment technology but adds a layer of artificial intelligence that analyses live images in real time. The system automatically reduces background noise across different 2D imaging modes and body areas, maintaining image quality even at very low radiation doses. This supports what clinicians call the ALARA principle, keeping radiation exposure as low as reasonably achievable without sacrificing the clarity needed to perform the procedure safely.

The labs are designed as multidisciplinary facilities, supporting teams across a wide range of specialties. Procedures the system can support include:

• Complex coronary interventions and chronic total occlusion procedures
• Structural heart interventions and peripheral vascular therapies
• Embolization and interventional oncology treatments
• Advanced aortic repairs
• Neurointerventional procedures and pain management

The platform also provides full 200-degree rotational 3D imaging, rapid 3D acquisitions, and system positioning precision of better than 0.5 mm. That level of mechanical accuracy gives physicians greater flexibility when they need to find a specific angle during a demanding case.

Why does it matter?

Dr. Georgie Thomas, Consultant Interventional Cardiologist and Head of Department at Burjeel Hospital Abu Dhabi, put it plainly: “In complex interventions, having a clear and accurate view of the anatomy throughout the procedure is critical. The new system gives us enhanced imaging and guidance when navigating challenging cases, while also helping us manage radiation and contrast use.”

For patients, better imaging means more precise diagnosis, fewer repeat procedures, and a higher chance that a complex case can be handled locally rather than referred abroad. For the clinical team, real-time guidance during demanding interventions reduces the cognitive load at precisely the moments when it matters most.

Burjeel Hospital Abu Dhabi has also recently received AHA Chest Pain accreditation, which strengthens its position in managing patients presenting with acute coronary symptoms. The new cath lab fits into a broader cardiac programme that runs from prevention and early diagnosis through to cardiac surgery, rehabilitation, and long-term management.

The context

This investment sits squarely within the direction the UAE’s health sector has been taking for the past several years. Abu Dhabi’s Department of Health has consistently pushed providers to build local capacity for complex tertiary care, reducing the need for medical travel and positioning the emirate as a regional centre of clinical excellence. The UAE’s broader ambitions, articulated through national health strategies and the UAE Vision 2031 framework, call for technology adoption in healthcare as both a quality measure and an economic one.

Across the GCC, cardiovascular disease remains the leading cause of death. So the pressure on health systems to expand interventional capacity is not an abstract policy goal. It’s a clinical reality that facilities like these are designed to meet. Burjeel’s expansion into Sharjah also signals something worth watching: the geographic spread of tertiary-level cardiac infrastructure beyond the two main UAE hubs. That broadens access, and access, in cardiovascular medicine, saves lives.

The post Burjeel Holdings installs AI-powered cath labs across two GCC hospitals appeared first on DH Arab.

The partnership is designed to give startups something that money alone cannot buy: structured access to diagnostic workflows, clinical validation environments, and a company that processes millions of patient samples annually across Europe and beyond. For founders building in areas like AI-assisted diagnostics, laboratory automation, or digital pathology, that kind of access can make the difference between a product that works in theory and one that works in a hospital.

How will it work?

The initial focus is on connecting Hub71-resident startups with Unilabs’ clinical and operational teams. Selected companies will have the opportunity to test and refine their solutions within real diagnostic settings, working alongside Unilabs specialists rather than just pitching to them. The collaboration is expected to cover several key areas:

• Clinical validation support for health tech products in development
• Access to Unilabs’ diagnostic network and subject-matter experts
• Co-development opportunities for new tools aligned with Unilabs’ service priorities
• Pathways toward commercial adoption within Unilabs’ operations

That last point matters. A partnership that ends at validation is useful. One that opens a door to procurement is far more valuable for a startup trying to scale.

Why does it matter?

Abu Dhabi has been deliberate about positioning itself as a serious destination for health innovation, not just a market for imported solutions. Initiatives like this one reflect a broader push to build local capability, attract global partners, and create conditions where health technology companies can grow regionally rather than simply pass through. Hub71’s model, backed by Abu Dhabi’s sovereign wealth and policy architecture, gives it the credibility to attract a company like Unilabs. And Unilabs, in turn, gains early visibility into emerging technologies that could reshape diagnostics over the next decade.

For startups in the Hub71 community, the practical benefit is significant. Clinical partnerships at this stage are rare and hard to negotiate independently. Having one structured into the ecosystem is a real advantage.

The context

This announcement fits into a wider pattern across the GCC, where governments and private sector players are moving beyond digital health rhetoric toward concrete infrastructure for innovation. Saudi Arabia’s Vision 2030 has placed health technology among its core diversification priorities. The UAE’s health sector strategy emphasises local R&D and reduced dependence on imported medical solutions. Against that backdrop, deals like this one between Hub71 and Unilabs are less about headlines and more about building the connective tissue that health innovation actually requires.

Diagnostics, often overlooked in favour of flashier health tech categories, is also having a moment globally. AI in pathology, automated lab systems, and data-driven early detection are attracting serious investment. Abu Dhabi, through moves like this, is making a case for being part of that conversation.

The post Hub71 and Unilabs join forces to bring health tech startups closer to clinical reality appeared first on DH Arab.

Beyond Bounds is not a journal, and it’s not a news feed. M42 describes it as a space where leading voices can share perspectives on the developments reshaping medicine and health systems globally. That includes AI-driven diagnostics, genomic research, digital health infrastructure and the policy questions that sit underneath all of it. The platform is open to contributors from across disciplines and geographies, and M42 has positioned it as genuinely global in scope rather than region-specific.

Still, the regional resonance is hard to ignore. M42 is headquartered in Abu Dhabi and is closely aligned with the UAE’s broader push to become a global hub for health innovation. That agenda sits at the heart of the country’s national strategy, which has invested heavily in genomics through the Emirati Genome Programme, in digital health infrastructure, and in attracting world-class medical institutions and talent. A platform like Beyond Bounds fits naturally into that picture.

How will it work?

Beyond Bounds will publish original perspectives from a wide range of contributors. M42 has indicated the platform will feature:

• Insights from leading scientists and medical researchers
• Policy analysis from health ministers and advisors
• Commentary from technology and business leaders working in health
• Perspectives on genomics, AI and the ethics of emerging medical tools

The platform is accessible online and is intended to reach a professional audience, including clinicians, health system administrators and decision-makers across both public and private sectors.

Why does it matter?

There is no shortage of health content online. But there is a genuine gap when it comes to high-quality, expert-led thinking that bridges clinical science, technology and policy in a way that is actually readable. M42 is betting that a curated, credible platform can fill that gap and, in doing so, strengthen its own profile as a thought leader rather than just a health operator.

For the GCC specifically, platforms like this also matter because they help build a regional voice in global health conversations. Too often, the major debates about the future of medicine are dominated by institutions based in the US or Europe. A platform anchored in Abu Dhabi, with genuine global reach, has the potential to shift that balance slightly.

The context

M42 was formed in 2022 through the merger of G42 Healthcare and Mubadala Health. It operates hospitals, clinics and diagnostic facilities, and has built a significant AI and genomics capability alongside its clinical work. Beyond Bounds is its first dedicated thought leadership initiative of this kind. Whether it becomes a genuine destination for serious health thinking or remains a polished content marketing exercise will depend on the quality and independence of the voices it attracts. The launch is the easy part.

The post M42 launches Beyond Bounds, a global platform for health thought leadership appeared first on DH Arab.

What’s the news?

Sheikh Hamdan approved the Dubai Longevity Authority’s strategy and operating budget at the body’s inaugural board meeting, formally activating the institution and signalling that longevity is now a funded government priority in Dubai, not simply a concept on paper. The DLA is tasked with positioning Dubai as a leading destination for longevity research, investment, and clinical innovation. Its mandate covers everything from preventive medicine and biotech to the regulatory environment needed to attract global players in the life-extension sector.

Why does it matter?

Longevity is one of the fastest-growing areas in global healthcare investment. Billionaire-backed research programmes, biotech startups, and academic institutions are racing to translate advances in genomics, AI-driven diagnostics, and cellular biology into practical interventions that extend healthy life. Until now, the dominant hubs have been the United States and parts of East Asia. Dubai is making a deliberate move to compete for that capital, talent, and scientific activity.

For the GCC more broadly, the stakes are real. Ageing populations, rising rates of chronic disease, and significant public healthcare expenditure are shared challenges across the region. A dedicated authority with a clear budget and political backing gives Dubai the institutional infrastructure to act, rather than simply participate in global conversations about longevity. It also fits cleanly within the UAE’s wider health agenda, which has consistently prioritised prevention, early intervention, and the use of data and technology to improve population outcomes.

The context

The Dubai Longevity Authority does not exist in isolation. It sits within a broader pattern of UAE health institution-building that includes the establishment of the Dubai Centre for Artificial Intelligence, significant investment in health data infrastructure, and ongoing work under the UAE’s National Strategy for Wellbeing. Saudi Arabia’s Vision 2030 has placed similar emphasis on preventive health and health system reform, meaning the two largest economies in the GCC are now both channelling resources into the future of healthcare.

What distinguishes the DLA is its specific focus on longevity as a scientific and commercial category. This is not a general public health body. It is designed to attract a particular kind of institution, researcher, and investor. The approval of its strategy by Sheikh Hamdan at the first board meeting suggests the authority has moved quickly from concept to operational readiness. The real measure of its ambition will come in the partnerships, regulations, and research outputs it generates over the next few years.

The post Dubai launches longevity authority with Crown Prince’s approval of inaugural strategy appeared first on DH Arab.